Bionano Genomics (BNGO) CEO receives 69,484 stock options grant

Rhea-AI Filing Summary

Bionano Genomics, Inc. reported that President and CEO, and director, Erik R. Holmlin received a grant of stock options on 02/02/2026. The award covers 69,484 options to buy common stock at an exercise price of $1.27 per share, expiring on 02/01/2036.

The options were awarded at a cost of $0 for the derivative itself and are held directly. They vest monthly over 48 months beginning one month after the vesting commencement date, so the option becomes fully vested and exercisable on the four-year anniversary of that date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Holmlin R. Erik

(Last) (First) (Middle)

C/O BIONANO GENOMICS, INC.

9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.27	02/02/2026		A		69,484		(1)	02/01/2036	Common Stock	69,484	$0	69,484	D

Explanation of Responses:

1. Each option award vests as follows: the shares subject to the option vest monthly over 48 months beginning on the one-month anniversary of the vesting commencement date, such that the option shall be fully vested and exercisable on the four-year anniversary of the vesting commencement date.

	/s/ Jonathan V. Dixon, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Bionano Genomics (BNGO) report for its CEO?

Bionano Genomics reported that President and CEO Erik R. Holmlin received a stock option grant. The award covers 69,484 options to purchase common stock, granted on February 2, 2026, and is reported as directly owned following the transaction.

How many stock options did Bionano CEO Erik Holmlin receive on 02/02/2026?

Erik Holmlin received 69,484 stock options in this transaction. These options give him the right to buy 69,484 shares of Bionano Genomics common stock, subject to the vesting schedule and the $1.27 per share exercise price disclosed in the filing.

What is the exercise price and term of the Bionano Genomics CEO options?

The options granted to the Bionano Genomics CEO have an exercise price of $1.27 per share. They expire on February 1, 2036, giving a long window during which the options can be exercised once vested under the stated schedule.

How do the Bionano Genomics CEO stock options vest over time?

The CEO’s stock options vest monthly over 48 months, starting on the one-month anniversary of the vesting commencement date. This means the options gradually become exercisable each month and are fully vested on the four-year anniversary of the vesting commencement date.

Is the Bionano Genomics CEO’s option grant reported as directly owned?

Yes, the filing reports the 69,484 stock options as directly owned by the CEO. The ownership form is indicated as “D” for direct, and there is no footnote stating that the options are held through another entity or with limited authority.

What role does the reporting person hold at Bionano Genomics (BNGO)?

The reporting person, Erik R. Holmlin, is both a director and an officer at Bionano Genomics. His officer title is President and Chief Executive Officer, reflecting his leadership role as disclosed in the insider transaction report.